Cargando…

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease, characterised by a relapsing-remitting pattern of inflammatory activity, with each relapse contributing to irreversible end-organ damage with detrimental effects on patients’ course, adding up to morbidity burden and shortening lif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, Alvaro, Enman, Yvonne, Parodis, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869695/ https://www.ncbi.nlm.nih.gov/pubmed/36699199 http://dx.doi.org/10.2147/PROM.S369584

Ejemplares similares

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2021)

How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023)

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review
por: Huang, Shirley P., et al.
Publicado: (2022)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2021)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
por: Schwarting, Andreas, et al.
Publicado: (2016)

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2022)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
por: Bell, Christopher F., et al.
Publicado: (2023)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
por: Collins, Christopher E., et al.
Publicado: (2020)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study
por: Wang, Dahai, et al.
Publicado: (2022)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
por: Schwarting, A, et al.
Publicado: (2016)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study
por: Sun, Fangfang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ktmfo6dbnqotdsc4ujkofb5md2